Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Dapagliflozin & Chronic Renal Failure / Chronic Kidney Disease (CKD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Dapagliflozin is approved by both the FDA and EMA for the treatment of chronic kidney disease (CKD), including in patients without type 2 diabetes. This approval is based on substantial evidence from trials such as DAPA-CKD, which demonstrated significant renal and cardiovascular benefits for this patient population
Heerspink et al. 2020 N Engl J Med 383:1436-1446
Patrick et al. 2021 J Gen Intern Med 36(9): 2915-2917
Nashar & Khalil 2022 Int J Nephrol Renovasc Dis 15: 289-308

…

References (Sources)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
Nashar & Khalil 2022 Int J Nephrol Renovasc Dis 15: 289-308
Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria
Patrick et al. 2021 J Gen Intern Med 36(9): 2915-2917
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink et al. 2020 N Engl J Med 383:1436-1446

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Dapagliflozin & Chronic Renal Failure / Chronic Kidney Disease (CKD)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat